Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Antidiabetic Effect of Memecylon Talbotianum Leaf Methanol Active Fraction in Male Wistar Rats

    wadmin2By wadmin2September 6, 2017Updated:August 12, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Bharathi T.R., Noor Mohamed Jameel, Behrouz Jalali Ghassam, Shrisha Naik Bajpe, Prakash HS*
    Department of Studies in Biotechnology, University of Mysore, Manasagangotri, Mysore, INDIA.

    Pharmacognosy Communications,2017,7,3,114-120.
    DOI:10.5530/pc.2017.3.17
    Published: September 2017
    Type: Original Article

    ABSTRACT

    Introduction: Memecylon talbotianum Brandis, (Melastomataceae) is an indigenous medicinal plant used in ethno-medicine including Ayurveda. However, the potential of this plant in controlling diabetes has not yet been evaluated. The role of M. talbotianum leaf extract on streptozotocin (STZ, 2-deoxy-2-(3- (methyl-3-nitrosoureido) d-glucopyranose- induced diabetes in male Wistar rats is investigated. Methods: The leaf extract was fractionated, its phytoconstituents were evaluated using HPLC and rats (6 animals in each group) were treated orally with M. talbotianum leaf methanol active fraction (MTLMAF) (100, 200 and 1000 mg/kg body weight) for 28 days with a single dose with metformin as a positive control. Biochemical parameters, histopathological and immunostaining studies were performed. Results: Administration of MTLMAF, significantly decreased the glucose level after four weeks (312 ± 14 mg/dL in diabetic animals compared to 134 ± 13 mg/dL in MTLMAF treated animals) and controlled the levels of TG (155 ± 63.55 units/dL in diabetic and 100.66 ± 13.31 units/dL in treated animals), LDL, HDL, VLDL and endogenous antioxidants (SOD, catalase and GSH). Histopathological studies substantiated the protective role of MTLMAF. MTLMAF also alleviated liver and pancreatic damage in STZdiabetic rats. HPLC analysis revealed that rutin, quercetin and protocatechuic acid were the major components present in M. talbotianum. The presence of these compounds in M. talbotianum is reported for the first time here and these compounds may be responsible for antidiabetic properties. Conclusion: Our study shows that MTLMAF could protect rats against streptozotocin induced diabetes, improves lipid profile, reduce the risk of oxidative stress and, ameliorate liver and pancreatic damage.

    Keywords: HPLC, STZ-diabetes, M. talbotianum, MTLMAF, Antidiabetic.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up